Events
O luns 20 de xaneiro ás 10:00 horas, Immacolata Maietta, do grupo de Inmunoloxía do CINBIO, defenderá a súa tese de doutoramento baixo o título “TARGETING EPIGENETIC MODIFICATIONS AND GENE EXPRESSION IN PANCREATIC CANCER: ANTITUMORAL EFFECT OF COMBINED THERAPIES".
Será no Salón de grao vello da Facultade de Ciencias, no campus de Vigo.
Resumo:
Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive pancreatic cancer, representing 85% of cases. Key mutations, such as in KRAS (90% of patients) and TP53, drive its progression, alongside epigenetic changes like DNA methylation and histone modifications. The tumor microenvironment (TME) plays a major role in therapy resistance by shielding cancer cells. This study tested a novel therapy combining epigenetic inhibitors (e.g., Entinostat), chemotherapy (gemcitabine), and siRNA targeting YAP-1 and FOSL1. This approach disrupts stroma-tumor interactions, reduces tumor growth, and enhances immune responses. Using a 3D organoid model, the therapy showed promise in overcoming PDAC resistance and improving treatment efficacy.
